For years, vertical consolidation has been a mainstay of the insurer playbook—blending payer, provider, pharmacy, and PBM assets into a single, integrated ecosystem designed to drive synergies, provide consistent margin performance, and withstand turbulence to any one part of the business. It’s a strategy that worked remarkably well through the 2010s and early 2020s. We may be reaching a turning point. Recent financial results across all national players —but especially from

Few categories in modern medicine have captured the imagination of patients, physicians, and investors as quickly as GLP-1 receptor agonists (GLP-1s). Originally developed for diabetes management, these drugs, popularized under brand names such as Ozempic, Wegovy, Mounjaro, and Zepbound, are redefining how we think about obesity, metabolic health, and even chronic disease prevention. And increasingly, GLP-1s are no longer just about controlling blood sugar. They have become c

With a new federal measure set to reward hospitals for participating in the Agency for Healthcare Research and Quality's (AHRQ) Patient Safety Organization (PSO) program starting next year—and a fresh government evaluation pushing for tweaks to the program to improve its effectiveness—PSOs have quickly moved from a relatively niche quality program to a potential strategy priority. PSOs play a strategic role by offering legal protections for safety event data and positioning o

Healthcare costs are accelerating faster than anyone predicted, and employers are struggling to keep up. And our team has been having an internal debate about a scenario that seemed unlikely even just a few years ago: could employer-sponsored insurance (ESI) finally be approaching its defined contribution moment—echoing the pension-to-401(k) transition that reshaped retirement benefits a generation ago? Employers have long relied on ESI to attract and retain workers, but risi

MAHA's recent strategic plan announced its intent to create a comprehensive real-world data asset to fuel research. However, any desire to move from data source to insight is likely to be more complex than merely acquiring some data. What potential pitfalls could lie ahead and what can other organizations learn from this?

All U.S. health systems, hospitals, provider groups, life sciences organizations, and national or regional payers are racing to scale AI....

When we last wrote about “Make America Healthy Again” (MAHA) earlier this year, the initiative was more of a slogan than a...

For the better part of the last decade, rural hospitals have been running on thin ice. In 2025, that ice appears poised to splinter. Core...

Over the course of the past few weeks, all five of the large, publicly traded health plans have hosted their second set of earnings calls...

Last week, Union Healthcare Insight had the privilege of gathering with an impressive group of hospital revenue cycle executives in...

The push toward healthcare price transparency started in earnest nearly 15 years ago, when the ACA highlighted the need for greater...

AI scribes for clinicians are clearly a compelling idea—but to what extent are adoption and results matching up? It can be hard to tell,...